BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16544888)

  • 1. Imatinib (Gleevec, Glivec) tumour tissue analysis by measurement of sediment and by liquid chromatography tandem mass spectrometry.
    Guetens G; Prenen H; De Boeck G; Highley M; de Wever I; van Oosterom AT; de Bruijn EA
    J Sep Sci; 2006 Feb; 29(3):453-9. PubMed ID: 16544888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous determination of AMN107 and Imatinib (Gleevec, Glivec, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection.
    Guetens G; Prenen H; De Boeck G; van Oosterom A; Schöffski P; Highley M; de Bruijn EA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 846(1-2):341-5. PubMed ID: 16962394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
    Titier K; Picard S; Ducint D; Teilhet E; Moore N; Berthaud P; Mahon FX; Molimard M
    Ther Drug Monit; 2005 Oct; 27(5):634-40. PubMed ID: 16175138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry.
    Guetens G; De Boeck G; Highley M; Dumez H; Van Oosterom AT; de Bruijn EA
    J Chromatogr A; 2003 Dec; 1020(1):27-34. PubMed ID: 14661754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate.
    Al-Hadiya BM; Bakheit AH; Abd-Elgalil AA
    Profiles Drug Subst Excip Relat Methodol; 2014; 39():265-97. PubMed ID: 24794909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.
    Parise RA; Ramanathan RK; Hayes MJ; Egorin MJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jul; 791(1-2):39-44. PubMed ID: 12798163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry.
    Zhang M; Moore GA; Fernyhough LJ; Barclay ML; Begg EJ
    Anal Bioanal Chem; 2012 Oct; 404(6-7):2091-6. PubMed ID: 22865010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.
    Bakhtiar R; Lohne J; Ramos L; Khemani L; Hayes M; Tse F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Mar; 768(2):325-40. PubMed ID: 11888061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection.
    Miura M; Takahashi N; Sawada K
    J Chromatogr Sci; 2011 May; 49(5):412-5. PubMed ID: 21549035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma.
    Zhang Y; Qiang S; Yu Z; Zhang W; Xu Z; Yang L; Wen A; Hang T
    J Chromatogr Sci; 2014 Apr; 52(4):344-50. PubMed ID: 23574742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of an high performance liquid chromatography-tandem mass spectrometry method for the determination of imatinib in rat tissues.
    Bianchi F; Caffarri E; Cavalli S; Lagrasta C; Musci M; Quaini F; Savi M
    J Pharm Biomed Anal; 2013 Jan; 73():103-7. PubMed ID: 22709608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography.
    Davies A; Hayes AK; Knight K; Watmough SJ; Pirmohamed M; Clark RE
    Leuk Res; 2010 Jun; 34(6):702-7. PubMed ID: 20004471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry.
    Bakhtiar R; Khemani L; Hayes M; Bedman T; Tse F
    J Pharm Biomed Anal; 2002 Jun; 28(6):1183-94. PubMed ID: 12049982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma.
    Moreno JM; Wojnicz A; Steegman JL; Cano-Abad MF; Ruiz-Nuño A
    Biomed Chromatogr; 2013 Apr; 27(4):502-8. PubMed ID: 23034891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays.
    Rezende VM; Rivellis A; Novaes MM; de Alencar Fisher Chamone D; Bendit I
    Drug Des Devel Ther; 2013; 7():699-710. PubMed ID: 23946646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence study of 400 and 100 mg imatinib film-coated tablets in healthy volunteers.
    Ostrowicz A; Mikołajczak PL; Wierzbicka M; Boguradzki P
    Acta Pol Pharm; 2014; 71(5):843-54. PubMed ID: 25362813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec capsules.
    Ivanovic D; Medenica M; Jancic B; Malenovic A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Feb; 800(1-2):253-8. PubMed ID: 14698262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of imatinib targeted delivery in human leukocytes.
    Kralj E; Žakelj S; Trontelj J; Pajič T; Preložnik Zupan I; Černelč P; Ostanek B; Marc J; Kristl A
    Eur J Pharm Sci; 2013 Sep; 50(1):123-9. PubMed ID: 23643738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture.
    Klawitter J; Zhang YL; Klawitter J; Anderson N; Serkova NJ; Christians U
    Biomed Chromatogr; 2009 Dec; 23(12):1251-8. PubMed ID: 19517424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental design in reversed-phase high-performance liquid chromatographic analysis of imatinib mesylate and its impurity.
    Medenica M; Jancic B; Ivanovic D; Malenovic A
    J Chromatogr A; 2004 Mar; 1031(1-2):243-8. PubMed ID: 15058589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.